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S U M M A R Y
Objectives: This phase III study assessed the safety and immunogenicity of MenACWY-CRM, a
quadrivalent meningococcal conjugate vaccine, administered with routine vaccines starting at 2
months of age.
Methods: Healthy infants received MenACWY-CRM in a two- or three-dose primary infant series plus a
single toddler dose. In addition, a two-dose toddler catch-up series was evaluated. Immune responses to
MenACWY-CRM were assessed for serum bactericidal activity with human complement (hSBA).
Reactogenicity and safety results were collected systematically.
Results: After a full infant/toddler series or two-dose toddler catch-up series, MenACWY-CRM elicited
immune responses against the four serogroups in 94–100% of subjects. Noninferiority of the two- versus
three-dose MenACWY-CRM infant dosing regimen was established for geometric mean titers for all
serogroups. Following the three-dose infant primary series, 89–98% of subjects achieved an hSBA 8
across all serogroups. Immune responses to concomitant routine vaccines given with MenACWY-CRM
were noninferior to responses to routine vaccines alone, except for pertactin after the two-dose infant
series. Noninferiority criteria were met for all concomitant antigens after the three-dose infant series.
Conclusions: MenACWY-CRM vaccination regimens in infants and toddlers were immunogenic and well
tolerated. No clinically meaningful effects of concomitant administration with routine infant and toddler
vaccines were observed.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Neisseria meningitidis is a leading cause of bacterial meningitis
and sepsis that can result in permanent disability or death within
hours in otherwise healthy individuals.1,2 Meningococcal disease
occurs globally and is characterized by an epidemiology with
ﬂuctuations in the incidence and occurrence of outbreaks and
epidemics.3,4 Six immunologically distinct serogroups (A, B, C,§ Some of the results reported in this manuscript were presented as a poster
entitled ‘‘Immunogenicity and safety of MenACWY-CRM, a quadrivalent meningo-
coccal conjugate vaccine, in infants’’ at the 31st Annual European Society for
Paediatric Infectious Diseases Meeting in Milan, Italy, May 28–June 1, 2013.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).W-135, X, and Y) are associated with signiﬁcant pathogenic potential
for invasive disease.5 The varied epidemiology of meningococcal
disease, its propensity to cause outbreaks, the severity of disease and
associated high case fatality rate, and its associated societal impact
constitute a uniquely challenging global health concern.
MenACWY-CRM (Menveo1; Novartis Vaccines and Diagnos-
tics) is a polysaccharide–CRM197 conjugate vaccine directed
against serogroups A, C, W-135, and Y.6 In early phase studies,
MenACWY-CRM was well tolerated and highly immunogenic in
infants, a group at high risk for meningococcal disease.7,8 Results
from the US study groups of a large phase III MenACWY-CRM
infant study illustrated robust immunogenicity and good tolera-
bility.9 This report describes results from the Latin American
study groups of the same study, in which infants received
MenACWY-CRM from 2 months of age. Speciﬁc objectives were to
assess the safety and immunogenicity of three- and four-doseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Subject disposition and vaccination schedule. The MenACWY-CRM three-dose series was given at 2, 6, and 12 or 13 months (LA1); the MenACWY-CRM four-dose
series was given at 2, 4, 6, and 16 or 17 months (LA3) or at 2, 4, 6, and 12 months (LA5); routine vaccinations only were given before 12 months of age for LA6. Toddler series
MenACWY-CRM doses were given at (12 or 13) + 15 months or at 18 months as indicated in the subgroups of LA6. All groups received routine infant vaccinations (DTaP, IPV,
Hib, HBV, rotavirus, and PCV7) at months 2, 4, and 6. LA1, LA2, LA4, LA5, and LA6 received concomitant vaccines (MMRV, PCV7, and HAV) at month 12. LA3 received
concomitant vaccines (DTaP and Hib) at month 16. (DTaP, diphtheria, tetanus, and acellular pertussis vaccine; HAV, hepatitis A vaccine; HBV, hepatitis B vaccine; Hib,
Haemophilus inﬂuenzae type b vaccine; IPV, inactivated poliovirus vaccine; MMRV, measles, mumps, rubella, varicella vaccine; PCV7, pneumococcal conjugate vaccine; LA,
Latin America.).
Table 1
Vaccinations and serum samples, per group, per time point
Cohort Group Procedure Age (months)
2 4 6 7 12 13 15 16 17 18
Immunogenicity LA1A MenACWY-CRM X X X
Routine vaccines X X X X
Serum sample X X X X
LA1B MenACWY-CRM X X X
Routine vaccines X X X X
Serum sample X X X X
LA2 MenACWY-CRM X X
Routine vaccines X X X X
Serum sample X X X X
LA3A MenACWY-CRM X X X X
Routine vaccines X X X X
Serum sample X X X X
LA3B MenACWY-CRM X X X X
Routine vaccines X X X X
Serum sample X X X X
LA4 MenACWY-CRM X X
Routine vaccines X X X X Xa
Serum sample X X X X
Safety only LA5 MenACWY-CRM X X X X
Routine vaccines X X X X
LA6A MenACWY-CRM X X
Routine vaccines X X X X
LA6B MenACWY-CRM X X
Routine vaccines X X X X
LA6C MenACWY-CRM X
Routine vaccines X X X X
DTaP, diphtheria, tetanus, and acellular pertussis; Hib, Haemophilus inﬂuenzae type b.
a MenACWY-CRM concomitant with DTaP and Hib.
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Table 2
Demographics and other baseline characteristics—all subjects
Groupa LA1 LA2 LA3 LA4 LA5 LA6
Three-dose
MenACWY-CRM
series
(2, 6, and 12 or
13 months)
n = 301
Two MenACWY-CRM
toddler doses
(12 and 15
months)
n = 148
Four-dose
MenACWY-CRM
series
(2, 4, 6, and 16
or 17 months)
n = 301
Two MenACWY-CRM
toddler doses
(12 and 15
months)
n = 150
Four-dose
MenACWY-CRM
series
(2, 4, 6, and
12 months)
n = 1426
One or two
MenACWY-CRM
toddler doses
(12 and 15, 13 and
15, or 18 months)
n = 711
Age (days) 68.3  8.3 67.8  8.3 67.7  8.3 67.5  8.0 65.0  9.4 65.1  9.1
Sex
Male 140 (47%) 76 (51%) 154 (51%) 69 (46%) 744 (52%) 353 (50%)
Female 161 (53%) 72 (49%) 147 (49%) 81 (54%) 682 (48%) 358 (50%)
Weight (kg) 5.3  0.7 5.4  0.7 5.3  0.7 5.3  0.7 5.6  0.7 5.6  0.7
Height (cm) 57.2  3.0 57.4  3.2 57.3  2.8 57.2  2.9 58.7  2.7 58.5  2.7
Met entry criteria
Yes 297 (99%) 146 (99%) 296 (98%) 148 (99%) 1412 (99%) 703 (99%)
No 4 (1%) 2 (1%) 5 (2%) 2 (1%) 14 (<1%) 8 (1%)
a All groups received routine infant vaccinations.
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Figure 2. Immunogenicity results for MenACWY-CRM at 7 months. (A) Percentage
of subjects with hSBA titers 8; values are the percentage of subjects and error bars
represent 95% CI. (B) GMTs after MenACWY-CRM; values are hSBA GMTs with 95%
CI error bars.
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toddler regimens, and concomitant administration of MenACWY-
CRM with routine infant and toddler vaccines.
2. Methods
2.1. Study design
This phase III, open label, randomized study of healthy infants
was conducted in Argentina, Colombia, and the USA (Clinical-
Trials.gov identiﬁer NCT00474526). The primary immunogenicity
objectives focused on the US study groups and are reported
separately.9 Predeﬁned secondary objectives evaluated in the Latin
American study groups are presented here. The protocol and
amendments were designed in accordance with the Declaration of
Helsinki and approved by the local ethics committees and national
regulatory authorities, as appropriate. Informed consent was
obtained from a parent or legal guardian. An independent, external
data monitoring committee monitored safety during the study.
Healthy infants were randomized 1:2 to receive routine infant
vaccines alone or concomitantly with MenACWY-CRM, in various
dosing schedules (Table 1). All immunogenicity groups (LA1–LA4)
received routine vaccines at 2, 4, and 6 months of age. Subjects in
LA1 received a three-dose infant/toddler MenACWY-CRM sched-
ule, consisting of a two-dose infant series (2 and 6 months) and a
toddler dose at 12 (LA1A) or 13 months (LA1B). LA3 subjects
received a four-dose infant/toddler MenACWY-CRM schedule: a
three-dose infant series (2, 4, and 6 months) and a toddler dose at
16 (LA3A) or 17 months (LA3B). Receipt of the toddler dose was
delayed in LA1B and LA3B so that the immune response to
concomitant vaccines could be compared between the group that
received the toddler MenACWY-CRM dose plus routine vaccines to
the group that had not yet received the toddler MenACWY-CRM
dose but had received routine vaccines (i.e., LA1A vs. LA1B, and
LA3A vs. LA3B). LA2 and LA4 received only routine vaccines in the
ﬁrst year of life, followed by a toddler catch-up series of
MenACWY-CRM at 12 and 15 months (Table 1).
Safety-only groups (LA5 and LA6) received MenACWY-CRM
plus routine vaccines (LA5: MenACWY-CRM plus routine vaccines
at 2, 4, 6, and 12 months) or routine infant vaccines only followed
by routine toddler vaccination and MenACWY-CRM at 12 and 15
months (LA6A). The study design was amended by request of the
regulatory authorities; the administration of MenACWY-CRM was
delayed to 13 months in a subgroup (LA6B) so that reactogenicity
and safety could be compared between subjects who received a
ﬁrst dose of MenACWY-CRM at 12 months of age (LA6A) withsubjects who had not yet received MenACWY-CRM (LA6B). A later
amendment created another subgroup with delayed administra-
tion of MenACWY-CRM until 18 months (LA6C) so that reacto-
genicity and safety could be compared between subjects who had
received the two-dose toddler series (LA6A) with those who were
as yet naive for meningococcal vaccine (LA6C) (Table 1).
MenACWY-CRM  + routine  vaccines  at  2 & 6 mo  (LA1 )
Routine vaccines  onl y at  2 & 6 mo  (LA2 )
MenACWY-CRM  + routine  vaccine s at  2,  4,  & 6 mo  (LA3)
Routine vaccines  onl y at  2,  4,  & 6 mo  (LA4 )
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Figure 3. Antibody persistence before the ﬁnal dose and immune response at 1 month after the ﬁnal dose of the three- and four-dose MenACWY-CRM infant/toddler series.
(A) Percentage of subjects with hSBA titers 8 before the ﬁnal dose. (B) hSBA GMTs before the ﬁnal dose. (C) Percentage of subjects with hSBA titers 8 at 1 month after the
ﬁnal dose. (D) hSBA GMTs at 1 month after the ﬁnal dose. Error bars represent 95% CI. For the infant series, subjects in the LA1 group received MenACWY-CRM at 2 and 6
months of age, while subjects in the LA3 group received MenACWY-CRM at 2, 4, and 6 months of age. Subjects in the LA2 and LA4 groups did not receive the infant series of
MenACWY-CRM vaccination. Antibody persistence was assessed in subjects at 12 (groups LA1 and LA2) or 16 (groups LA3 and LA4) months of age, whereas responses at 1
month after the ﬁnal dose were assessed in subjects at 13 (LA1A) or 17 (LA3A) months of age.
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blinding until subject randomization. Subjects were randomized
and stratiﬁed by study site using two computer-generated lists (for
immunogenicity and safety groups) provided by the sponsor. The
immunogenicity group was enrolled at pre-selected sites in
Argentina.
2.2. Study subjects
Healthy 55–89-day-old infants with birth weight 2.5 kg and
gestational age 37 weeks were eligible. Infants with prior
exposure to disease caused by or vaccination against N. meningi-
tidis, Corynebacterium diphtheriae, Clostridium tetani, Bordetella
pertussis, poliovirus, Haemophilus inﬂuenzae type b (Hib), Strepto-
coccus pneumoniae, or hepatitis B virus (HBV) were excluded, with
the exception that a birth vaccination against HBV was permitted.
Infants with contraindications for vaccination, including allergy tovaccine components, or signiﬁcant infection within 7 days or fever
within 3 days of screening, were excluded.
2.3. Vaccines
MenACWY-CRM was prepared by extemporaneous mixing of
the lyophilized MenA component with the liquid MenCWY
component immediately before intramuscular (IM) injection into
the right thigh. Each 0.5-ml dose contained 10 mg of MenA
oligosaccharide and 5 mg each of oligosaccharides from MenC,
MenW-135, and MenY conjugated to CRM197.
10 Concomitant
vaccines were administered either IM or subcutaneously into the
left thigh, as appropriate. In subjects receiving only routine
vaccines, Hib vaccine was administered IM into the right thigh as
the control for local reactogenicity at 2, 4, 6, and 16 months,
whereas pneumococcal conjugate vaccine (PCV7) served as the
control for the 12-month reactogenicity assessments.
Figure 4. Seroresponse to the toddler catch-up series after one and two doses.
Subjects in the LA2 and LA4 groups received the ﬁrst MenACWY-CRM vaccination at
12 months and the second dose at 15 months. The post-ﬁrst-dose blood draw was
taken at month 13 (LA2), and the post-second-dose blood draw was taken at month
16 (LA4). The pre-toddler vaccine serum samples were collected from both groups
at month 12 (before vaccination), but only the results from LA2, the most variable
results, are shown.
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Figure 1. Concomitant vaccines included combined diphtheria–
tetanus–acellular pertussis (DTaP)–hepatitis B virus (HBV)–inac-
tivated polio vaccine (IPV) (Pediarix1; GlaxoSmithKline); DTaP
booster (Infanrix1; GlaxoSmithKline); Hib–tetanus toxoid (TT)
(ActHIB1; Sanoﬁ Pasteur); PCV7 (Prevnar1; Pﬁzer, formally
Wyeth); rotavirus vaccine (RotaTeq1; Merck & Co.); measles,
mumps, rubella and varicella vaccine (MMRV) (ProQuad; Merck &
Co.) or measles, mumps and rubella vaccine (M-M-R1 II; Merck &
Co.); varicella vaccine (Varivax1; Merck & Co.); and hepatitis A
vaccine (HAV) (Havrix1; GlaxoSmithKline).
2.4. Immunogenicity assessments
Immunogenicity was assessed by serum bactericidal activity
using human complement (hSBA) with the percentage of subjects
with titers 8 and geometric mean titers (GMTs) against each
serogroup at relevant time points, as described previously.7
Diphtheria, tetanus, Hib, pneumococcus, and pertussis antigen
(pertussis toxin (PT), ﬁlamentous hemagglutinin (FHA), and
pertactin) antibody concentrations were evaluated using ELISA,
and seroresponse to poliovirus was assessed by viral neutralization
assay.2.5. Safety assessments
Local and systemic reactions and all adverse events were
solicited for seven days post-vaccination after all vaccination visits.
Adverse events (AE) that required a physician’s visit, resulted in
premature withdrawal, or were considered serious (SAE), were
collected during the entire study period. Investigators assigned AE
severity and assessed the relationship to vaccination.
2.6. Statistical analyses
Sufﬁciency of the immune response was prespeciﬁed as met if
the lower limit of the two-sided 95% conﬁdence interval (LL 95% CI)
around the percentage of subjects with hSBA titers 8 was 80%
for serogroup A and 85% for serogroups C, W-135, and Y. The
noninferiority criterion for the two- versus three-dose infant
MenACWY-CRM series required that the LL 95% CI for the ratio of
GMTs (LA1/LA3) was >0.5.
Noninferiority of concomitant vaccine response was prespeci-
ﬁed as the LL 95% CI for the differences in seroresponse rates
>10%, except for poliovirus for which the threshold was >5%.
For pertussis antigens, noninferiority was deﬁned as a geometric
mean concentration (GMC) ratio (GMCMenACWYCRM+routine/
GMCroutine vaccines alone) >0.67, with pertussis seroresponse as an
additional secondary noninferiority endpoint. Noninferiority of the
pneumococcal antigens was prespeciﬁed as the LL 95% CI for the
ratio of the GMCs for all pneumococcal serotypes >0.50.
Sample sizes were based on the response in this age group in
previous studies.7,11 The immunogenicity analysis was based on
the per-protocol (PP) population: all subjects without major
protocol deviations who received all appropriately timed vaccine
doses and provided appropriately timed evaluable serum samples.
The safety population included all enrolled subjects who received
at least one vaccine dose and provided any safety data.
3. Results
All 900 subjects enrolled in the immunogenicity groups (LA1–
LA4) were enrolled in Argentina; the 2137 subjects enrolled in the
safety-only groups (LA5 and LA6) were enrolled in Argentina and
Colombia (Figure 1). Enrollment began April 19, 2007, and follow-
up was completed November 13, 2009. For the immunogenicity
analysis, the PP population included 825 subjects after the infant
series and 629 subjects after toddler vaccination. Demographic
characteristics are shown in Table 2.
3.1. Immunogenicity of the infant/toddler MenACWY-CRM series
Measured at 1 month post-infant series, immune responses to
the two-dose (LA1) and three-dose series (LA3) were similar for
serogroups C, W-135, and Y: 94–99% and 97–98% of subjects had
hSBA titers 8 after the two-dose and three-dose series,
respectively (Figure 2). Responses for serogroup A were higher
in subjects who received the three-dose (89%) than the two-dose
infant series (74%) (Figure 2). The percentages of subjects with
hSBA titers 8 after the two-dose infant series were noninferior to
the three-dose series (LL 95% CI >10%) for all serogroups except A
(Figure 2A). Using the GMT endpoint, the two-dose infant series
was noninferior for all serogroups (ratios of GMTs >0.5)
(Figure 2B).
Antibody persistence prior to the toddler dose is shown in
Figure 3. At 12 months of age, 25–85% of subjects who received the
two-dose infant series had hSBA 8; at 16 months of age, 15–63%
of subjects who received the three-dose infant series had hSBA 8
(Figure 3A). GMTs were 4.3–31.0 for the two-dose and 3.0–14.0 for
the three-dose infant series (Figure 3B). The majority of subjects
Figure 5. Seroresponses to routine vaccines (DTaP, IPV, HBV, pneumococcal conjugate, Hib) given with (LA3) and without MenACWY-CRM (LA4) were compared at 7 months.
Blood was drawn at month 7. Values are the percentage of subjects with 95% CI error bars. (FHA, ﬁlamentous hemagglutinin; HBV, hepatitis B virus; Hib, Haemophilus
inﬂuenzae type b; PnC, pneumococcal conjugate vaccine.)
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antibodies.
One month after the full three-dose and four-dose infant/
toddler series (at 13 and 17 months, respectively), the percentages
of subjects with hSBA titers 8 were 94–99% for the three-dose
series (LA1A) and 95–100% for the four-dose series (LA3A)
(Figure 3C). Both schedules achieved the pre-deﬁned immunoge-
nicity criteria for sufﬁciency; the LL 95% CI was 80% for serogroup
A and 85% for serogroups C, W-135, and Y. GMTs were similar for
both schedules (Figure 3D).
3.2. Immunogenicity of the two-dose toddler catch-up series
Two groups (LA2 and LA4) received only routine vaccines
during their ﬁrst year, followed by MenACWY-CRM toddler ‘catch-
up’ vaccinations at 12 and 15 months. Serum samples were
collected from LA2 at 1 month after the ﬁrst dose (at 13 months of
age) and from LA4 at 1 month after the second dose (at 16 months
of age). One month after the ﬁrst toddler vaccination, 72–91% of
subjects achieved hSBA titers 8 and GMTs were 15–45. One
month after the second toddler vaccination, 97–100% of subjects
achieved hSBA titers 8 and GMTs were 128–501 (Figure 4).
3.3. Response to routine vaccines
Seroresponses to routine vaccines (DTaP, IPV, HBV, pneumo-
coccal conjugate, Hib) given with (LA3) and without MenACWY-
CRM (LA4) were compared at 7 months (Figure 5). The difference
in seroresponse rates (PLA3 – PLA4) for poliovirus antigens rangedfrom 1% to 0 with the LL 95% CI >5% for each, achieving
noninferiority (Figure 5A). Noninferiority was also achieved for
each pneumococcal antigen, with the LL 95% CI around the
difference in seroresponse rates (PLA3  PLA4) >10% for each
(Figure 5B). The LL 95% CI for the difference in seroresponse rates
(PLA3  PLA4) for diphtheria, tetanus, hepatitis B, Hib, and
pertussis antigens PT and FHA was >10%, achieving noninfer-
iority (Figure 5A and C).
The ratio of GMCs (GMCLA3/GMCLA4) for pertussis antigens
ranged from 0.80 to 0.93, with the LL 95% CI >0.67 for PT and FHA
(noninferiority achieved) and 0.66 for pertactin (noninferiority not
achieved). The ratio of GMCs or GMTs (poliovirus only) for the
other antigens ranged from 0.75 to 1.07 (LL 95% CI >0.50, for each).
The immune response (GMCs) to PCV7 administered concomi-
tantly with MenACWY-CRM at 12 months of age (LA1A) was
noninferior to responses in subjects who received PCV7 alone
(LA1B) (LL 95% CI >0.50, for each).
Immune responses to DTaP and Hib given with a fourth dose of
MenACWY-CRM or alone at 16 months were examined at 17
months (Figure 6). The LL 95% CI around the difference in
percentages of seroresponders (PLA3A  PLA3B) against diphtheria,
tetanus, Hib, PT, and pertactin (4-fold rise) were >10%,
achieving noninferiority. Noninferiority was not achieved for
FHA, for which the LL 95% CI was 10.2%. The ratio of GMCs
(GMCLA3A/GMCLA3B) for Hib, diphtheria, and tetanus antigens
ranged from 0.86 to 1.05 with the LL 95% CI >0.50 (noninferiority
achieved) for each antigen. The ratio of GMCs for PT, FHA, and
pertactin antigens ranged from 1.11 to 1.21 with LL 95% CI >0.67
for all pertussis antigens (noninferiority achieved).
020
40
60
80
100
MenACWY-CRM + Hib,  DTaP  (LA3 A)
Hib, DTaP (LA3B)
Se
ro
re
sp
on
de
rs
, %
(A)
Hib Diphth eria Tetanu s Pertuss is FHA Pertactin
≥1.0  
μg/mL
≥1.0
IU/mL
 ≥1.0
IU/mL
≥4-fold  increas e
G
M
C
s 
(lo
g 
sc
al
e)
Hib         Diphtheri a     Tetanu s      Pertussis          FHA        Pertactin
(B)
100  99        98   98           98    98
89   84         87    88           89    88
117  101         118  101         118  101         113   99           113  99            113  99
1
10
100
1000
35   41
5.4  5. 2 6.2  6.6
68  62
245  215 238 19 7
117  101         118   101         118  101         113  99           113   99          113   99
Figure 6. Seroresponse after the fourth dose of MenACWY-CRM at 16 months of age. Subjects in the LA3A group received Hib and DTaP vaccines concomitantly with a fourth
dose of MenACWY-CRM at 16 months of age. Subjects in the LA3B group received the Hib and DTaP vaccines without a concomitant dose of MenACWY-CRM at 16 months of
age. Serum samples were collected at 17 months. (A) Percentage of subjects with a seroresponse; values are the percentage of subjects with 95% CI error bars. (B) GMTs; values
are the geometric mean concentrations/titers with 95% CI error bars. (FHA, ﬁlamentous hemagglutinin; Hib, Haemophilus inﬂuenzae type b vaccine.)
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The incidence of local and systemic reactions within seven days
after the ﬁrst (at 2 months) vaccination was similar in groups that
received routine vaccines with (LA1, LA3, LA5) or without
MenACWY-CRM (LA2, LA4, LA6) (Table 3). The most common
systemic reactions were sleepiness (31–54%) and irritability (33–
42%), with 5% of subjects reporting severe reactions. Fever of
38 8C was reported for 3–15% of subjects. Analgesic and/or
antipyretic medications were used in 51–72% of subjects.
AEs were summarized for the infant series, between the infant
series and toddler dose, and from 12 to 18 months of age (Table 4).
For the infant series, AE rates were similar in groups that received
the three-dose infant MenACWY-CRM series plus routine vaccines
(LA3 + LA5, 59%) and those that received routine vaccines only
(LA2 + LA4 + LA6, 55%). The lower AE rate reported after the two-
dose infant MenACWY-CRM series (LA1, 34%) is likely due to the
lower number of infant series visits where all adverse events were
collected for LA1 (two visits) than LA3 and LA5 (three visits). AE
rates were similar across groups between the infant series andtoddler dose (20–30%), and from 12 to 18 months of age (25–27%).
SAEs occurred in 4% of subjects across all groups. Three deaths
occurred, none of which were considered related to MenACWY-
CRM vaccination: one due to a lung infection, one due to a car
accident trauma, and one due to sepsis with a history of tetralogy
of Fallot.
4. Discussion
This study demonstrates that at the completion of a three-dose
(2, 6, and 12 months) or four-dose (2, 4, 6, and 16 months)
MenACWY-CRM infant/toddler regimen, a robust immune re-
sponse is produced against all four serogroups. An improved early
response at 7 months of age against serogroup A was demonstrated
by the additional dose in the ﬁrst year of life. Based on the
percentage of subjects with an hSBA titer 8, noninferiority of the
two- versus three-dose infant series was established for ser-
ogroups C, W, and Y, but not for serogroup A. However, based on
GMTs, noninferiority was established for the two-dose infant
Table 3
Local and systemic reactions during the 7-day period after the ﬁrst infant series vaccination at 2 months
Vaccinations received
at 2 months
LA1
Routinea +
MenACWY-CRM
n = 301
LA2
Routine
n = 148
LA3
Routine +
MenACWY-CRM
n = 301
LA4
Routine
n = 150
LA5
Routine +
MenACWY-CRM
n = 1424
LA6
Routine
n = 709
Localb
Tenderness Any 154 (51%) 96 (65%) 170 (56%) 95 (63%) 916/1423 (64%) 501 (71%)
Cried when
injured limb
moved
30 (10%) 19 (13%) 22 (7%) 20 (13%) 92/1423 (6%) 74 (10%)
Erythema (mm) Any 86 (29%) 62 (42%) 86 (29%) 65 (43%) 542/1423 (38%) 273 (39%)
>50 mm 0 0 1 (<1%) 1 (1%) 1/1423 (<1%) 4 (1%)
Induration (mm) Any 74 (25%) 56 (38%) 72 (24%) 53 (35%) 249/1423 (17%) 126 (18%)
>50 mm 1 (<1%) 0 0 0 2/1423 (<1%) 0
Systemic
Rash Any 11 (4%) 6 (4%) 12 (4%) 4 (3%) 98/1423 (7%) 55 (8%)
Urticarial 7 (2%) 2 (1%) 4 (1%) 1 (1%) 54/1423 (4%) 26 (4%)
Change in eating habits Any 37 (12%) 30 (20%) 44 (15%) 16 (11%) 250/1423 (18%) 127 (18%)
Severe 2 (1%) 0 0 1 (1%) 6/1423 (<1%) 4 (1%)
Sleepiness Any 106 (35%) 53 (36%) 93 (31%) 52 (35%) 727/1423 (51%) 381 (54%)
Severe 8 (3%) 2 (1%) 6 (2%) 4 (3%) 21/1423 (1%) 14 (2%)
Persistent crying Any 95 (32%) 53 (36%) 87 (29%) 43 (29%) 479/1423 (34%) 258 (36%)
Severe 5 (2%) 3 (2%) 11 (4%) 8 (5%) 29/1423 (2%) 21 (3%)
Irritability Any 121 (40%) 62 (42%) 99 (33%) 59 (39%) 508/1423 (36%) 240 (34%)
Severe 7 (2%) 2 (1%) 4 (1%) 2 (1%) 22/1423 (2%) 2 (<1%)
Vomiting Any 25 (8%) 9 (6%) 29 (10%) 17 (11%) 215/1423 (15%) 100 (14%)
Severe 0 0 1 (<1%) 1 (1%) 2/1423 (<1%) 1 (<1%)
Diarrhea Any 42 (14%) 20 (14%) 44 (15%) 22 (15%) 222/1423 (16%) 96 (14%)
Severe 1 (<1%) 0 1 (<1%) 0 2/1423 (<1%) 2 (<1%)
Fever (38 8C) Yes 15 (5%) 12 (8%) 18 (6%) 5 (3%) 211/1422 (15%) 97/708 (14%)
Other
Temperature (8C) <38.0 8C 286 (95%) 136 (92%) 283 (94%) 145 (97%) 1211/1422 (85%) 611/708 (86%)
40.0 8C 0 0 0 0 1/1422 (<1%) 0
Analgesic/antipyretic
medications used
Yes 155 (51%) 75 (51%) 159 (53%) 80 (53%) 996 (70%) 510 (72%)
a Routine vaccinations given at 2 months were: tetanus, diphtheria, and acellular pertussis (DTaP), inactivated poliovirus vaccine (IPV), hepatitis B vaccine (as Pediarix1),
Haemophilus inﬂuenzae type b vaccine (as ActHIB1), rotavirus vaccine (RotaTeq1), and pneumococcal conjugate vaccine (Prevnar1).
b Local reactions evaluated in the control group at the pneumococcal vaccine injection site.
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serogroups.
Effects of MenACWY-CRM on immune responses to routine
infant vaccinations were minimal. Noninferiority of the immuneTable 4
Overview of adverse events; number (%) of subjects with adverse events
Infant series MenACWY-CRM
Two-dose infant series
(LA1)
n = 301
Any AEs 103 (34%) 
SAEs 6 (2%) 
AEs leading to premature withdrawals 0 
Deaths 0 
Between infant series and toddler dose MenACWY-CRM
Three-dose infant/todd
(LA1)
n = 301
Any AEs 90 (30%) 
SAEs 9 (3%) 
AEs leading to premature withdrawals 0 
Deaths 0 
12–18 months (subjects who completed the trial) 
Any AEs 
SAEs 
AEs leading to premature withdrawals 
Deaths 
AE, adverse event; SAE, serious adverse event.responses to routine vaccines administered concomitantly with
the two-dose MenACWY-CRM infant series compared with
responses to routine vaccines only was demonstrated for
pneumococcal, Hib, HBV, IPV, diphtheria, tetanus, and all pertussisMenACWY-CRM
Three-dose infant series
(LA3 + LA5)
n = 1725
Routine only
(LA2 + LA4 + LA6)
n = 1007
1020 (59%) 557 (55%)
65 (4%) 41 (4%)
0 0
0 0
ler series
MenACWY-CRM
Four-dose infant/toddler series
(LA3 + LA5)
n = 1620
MenACWY-CRM
Toddler
(LA2 + LA4 + LA6)
n = 945
329 (20%) 219 (23%)
60 (4%) 35 (4%)
1 (<1%) 1 (<1%)
1 (<1%) 0
MenACWY-CRM
Four-dose infant/toddler
(LA5)
n = 1270
Routine only
18 months
(LA6C)
n = 174
338 (27%) 44 (25%)
35 (3%) 0
2 (<1%) 1 (<1%)
2 (<1%) 0
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comparison for pertactin (data not shown). Noninferiority to all
concomitant vaccine antigens was established after the three-dose
MenACWY-CRM infant series, with the exception of the GMC ratio
comparison of pertactin.
Antibody persistence after the MenACWY-CRM infant series
was evident at 12 and 16 months. At 12 or 16 months of age,
subjects who had received the two- or three-dose infant series,
respectively, had higher antibody levels than control subjects,
particularly for serogroups W-135 and Y. However, the noticeable
drop in protective antibodies from 1 month post-infant series,
especially for serogroups A and C, highlights the importance of a
toddler dose to ensure adequate protection in this vulnerable
group.
One month after the toddler dose of the full three- and four-
dose infant/toddler MenACWY-CRM series (13 or 17 months,
respectively), robust immune responses were evident to each of
the four serogroups, with hSBA titers 8 in 94–100% of subjects.
Subjects who received routine vaccinations only in the ﬁrst
year, received two toddler catch-up doses of MenACWY-CRM at 12
and 15 months of age. Sufﬁciency of the immune response to
MenACWY-CRM was demonstrated after the two-dose toddler
regimen, with protective antibodies to each of the four serogroups
in 97–100% of subjects. Although the three- and four-dose infant/
toddler regimens induce protective antibodies at an earlier age, the
current data show that the two-dose toddler regimen can be used
to induce protective antibodies in toddlers who have not been
vaccinated previously against meningococcal disease.
Responses to concomitant toddler vaccines (DTaP and Hib)
given with MenACWY-CRM were noninferior, except for the
percentage of subjects with seroresponses to FHA. GMCs for
pneumococcal antibodies in response to a fourth dose of
pneumococcal vaccine were noninferior to responses produced
when administered concomitantly with MenACWY-CRM at 12
months. Taken together, we conclude that MenACWY-CRM may be
administered concomitantly with routine infant and toddler
vaccines without clinically relevant immunological interference.
Rates of reactogenicity and safety events for groups receiving
MenACWY-CRM were similar to those who received routine
vaccinations only. The most commonly reported local reaction was
tenderness, and the most common systemic reactions were
irritability and sleepiness. Most reactions were mild to moderate
in severity. After each infant vaccination, the percentages of
subjects with local reactions were slightly lower than after the
previous vaccination. Systemic reactions were similar in subjects
who received MenACWY-CRM plus routine vaccination compared
with those who received routine vaccinations only.
During the study, the most commonly reported AEs were
nasopharyngitis, bronchiolitis, pyrexia, and bronchitis. Fewer than
6% of subjects reported AEs that were at least possibly related to
MenACWY-CRM, and no deaths were associated with MenACWY-
CRM vaccination.
The results of this analysis are consistent with results reported
for the US groups of the study,9 in which a three-dose infant series
(at 2, 4, and 6 months) was followed by a fourth (toddler)
vaccination at 12 or 13 months of age. Across both geographic
regions, the two- or three-dose infant regimens, the full three- or
four-dose infant/toddler regimens, and a two-dose toddler
regimen of MenACWY-CRM, all produced adequate immunoge-
nicity with little effect on routine concomitant vaccinations.
In conclusion, MenACWY-CRM was shown to be highly
immunogenic in infants when given as a three- or four-dose
infant/toddler series with concomitant infant and toddler vaccina-
tions. Administration of MenACWY-CRM to infants did not affectresponses to concomitantly administered vaccines in a clinically
meaningful way. Given the high risk of invasive meningococcal
disease during infancy, earlier vaccination is optimal; however, the
robust immune response elicited by the two-dose MenACWY-CRM
toddler catch-up series demonstrates that this regimen can be
offered to unimmunized toddlers. Reactogenicity and adverse
events were generally similar in the MenACWY-CRM and control
groups, and the most frequently observed events were expected.
The results from various dosing regimens assessed in infants and
toddlers consistently illustrated that MenACWY-CRM effectively
induces antibody protection to serogroups A, C, W-135, and Y;
these results conﬁrm that MenACWY-CRM is a valuable tool for
reducing the burden of invasive meningococcal disease in very
young children, and will also assist local decisions about vaccine
administration.
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